Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Equity (2016 - 2025)

Editas Medicine (EDIT) has disclosed Return on Equity for 10 consecutive years, with 12.11% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 1108.0% to 12.11% in Q3 2025 year-over-year; TTM through Sep 2025 was 12.11%, a 1108.0% decrease, with the full-year FY2024 number at 0.98%, down 55.0% from a year prior.
  • Return on Equity was 12.11% for Q3 2025 at Editas Medicine, down from 5.75% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.27% in Q2 2021 to a low of 12.11% in Q3 2025.
  • A 5-year average of 1.55% and a median of 0.52% in 2024 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: surged 32bps in 2021, then plummeted -1108bps in 2025.
  • Editas Medicine's Return on Equity stood at 0.34% in 2021, then crashed by -68bps to 0.57% in 2022, then grew by 25bps to 0.43% in 2023, then crashed by -258bps to 1.53% in 2024, then plummeted by -691bps to 12.11% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Return on Equity are 12.11% (Q3 2025), 5.75% (Q2 2025), and 2.55% (Q1 2025).